MILAN (AIMnews.it) - In 2017 Kolinpharma achieved 4.1 million revenues, 62% more than the 2.5 million of the previous year. EBITDA rose from 0.26 to 0.6 million, while the net loss decreased from 0.37 to 0.07 million euros. "2017 was a year of strong growth for the company in terms of revenues and margins, confirming a winning company strategy, centered on significant investments in innovation and development of a widely diversified offer - explained Rita Paola Petrelli, chairman of innovative SMEs operating in the field of nutracetics - Also the strengthening of the commercial network is particularly strategic in order to raise awareness of the efficacy of nutraceutical products and on the peculiarities of our brands. In 2017 we started a path of strong corporate structure and through the listing on AIM Italia on March 9, 2018 we aim to accelerate scientific research projects for the development of products with new pharmaceutical forms". At the end of 2017, equity was 1.2 million, while the net financial position was negative by 2.5 million "due to greater investments made mainly for research and development activities and for the launch and consolidation of the sales network". In fact, during the 2018 financial year, the company intends to focus on the development of products for therapy with high growth rates and with innovative formulations, and from a commercial point of view, to widen the Medical-Scientific Informatics network to achieve optimal coverage of the territory and the specialist medical target of interest and obtain a significant market position ".